SecBot SecBot

INCY drug pipeline

INCYTE CORP · 4 rated drugs
$120.27
−0.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.3%
1-day, median of 10 events
IV rank
40
IV 44% · HV 32%
Rated drugs
4
2 mixed · 2 neutral
Phase 3 trials
11
9 with results posted

Upcoming catalysts

2 dated
  1. Dec 26, 2026
    Povorcitinib
    Phase 3 primary completion
  2. Jan 6, 2027
    INCA034176
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3 (recruiting)
Time to marketPhase 3 enrollment began September 2026. With primary completion estimated for June 2029 and regulatory filing thereafter, potential FDA approval for ET is at least 3-4 years away if Phase 3 succeeds. The MF registrational program is still in planning.

INCA033989 anti-mutant calreticulin monoclonal antibody inca033989 Updated Oct 29

What to watch

INCA033989 has no imminent binary catalyst. The Phase 3 EXCALIBUR-ET2 trial started enrollment in September 2026 with primary completion estimated for mid-2029, and the registrational program for myelofibrosis remains in planning. Near-term share-price moves for INCY will be driven by commercial execution on Jakafi, Opzelura, and other pipeline readouts (povorcitinib, latarcibart) rather than INCA033989-specific news.

Bull case
  • First-in-class targeted therapy for CALR-mutant MPNs with no approved direct competitor, addressing a distinct biomarker-defined population (~25-30% of ET/MF patients)
  • Phase 1 data at EHA 2026 showed 87% hematologic response in ET (70% complete) and meaningful spleen reductions in MF, with rapid median ~2-week time to response
  • FDA Breakthrough Therapy designation (December 2025) provides expedited development pathway and signals agency interest
Bear case
  • Phase 3 data for the lead ET indication is years away (primary completion ~2029), so no near-term binary catalyst to drive stock
  • The ET and MF markets already have multiple generic and branded treatments (hydroxyurea, anagrelide, interferons, Jakafi, fedratinib, pacritinib) that physicians are familiar with
  • Phase 1 sample sizes are small; durability, safety profile, and registration-level efficacy remain unproven
● neutral
Impact
PhasePhase 3
Time to marketLikely 2029 or later. The Phase 3 NEXERA-303 primary completion is estimated at December 2028, with topline data expected in 2029. If positive, an NDA filing would follow, putting potential approval no earlier than 2030.

INCA33890 anti-PD-1/anti-TGFβR2 bispecific antibody Updated Oct 29

What to watch

The next hard catalyst is the Phase 3 NEXERA-303 topline readout, but that is not expected until 2029, more than 12 months away. Investors should watch for interim Phase 1/2 combination updates (including the new muzastotug combo trial) and any biomarker data that could refine the Phase 3 probability of success. Incyte's Q3 2026 earnings were reported today (Oct 29, 2026); pipeline updates in the earnings call may provide additional color on NEXERA-303 enrollment.

Bull case
  • MSS colorectal cancer represents a major unmet need (over 150,000 new US cases/year) with essentially no effective immunotherapies -- a successful INCA33890 could address a multi-billion-dollar market.
  • Phase 1 combination data (71.4% ORR with FOLFOX/bevacizumab in first-line MSS CRC) are compelling for an immunotherapy in a checkpoint-refractory indication, supporting the Phase 3 hypothesis.
  • The drug's differentiated mechanism (targeting PD-1 rather than PD-L1, and TGFβR2 only on co-expressing cells) may avoid the toxicity issues that plagued earlier TGFβ/PD-L1 bifunctional agents like bintrafusp alfa.
Bear case
  • Topline Phase 3 data are not expected until 2029, so INCA33890 provides no near-term catalyst for INCY shares and the stock will be driven by approved products and other pipeline assets.
  • The TGFβ/PD-(L)1 dual-targeting space has been littered with failures, including Merck KGaA/Pfizer's bintrafusp alfa which failed multiple Phase 3 trials due to toxicity and lack of efficacy.
  • Phase 1 monotherapy activity in MSS CRC was modest (12% ORR), raising questions about whether the combination benefit observed is driven by chemotherapy rather than INCA33890.
◆ mixed
Impact
PhasePhase 3
Time to marketLikely 2029 or later, based on the estimated primary completion date of May 2029 for the MAESTRA 2 pivotal trial, assuming positive results and a subsequent regulatory filing.

INCB123667 Updated Oct 29

What to watch

No hard binary catalyst (pivotal readout or FDA decision) is expected for INCB123667 within the next 12 months. The MAESTRA 2 Phase 3 trial started December 2025 with estimated completion in 2029. Investors should watch for interim data updates at medical conferences like ASCO 2027 (June) or ESMO 2027 (October), and for enrollment progress updates in Incyte quarterly earnings calls. Near-term value drivers for INCY stock are more likely to come from approved products (Jakafi, Opzelura) and nearer-term pipeline readouts for other assets like povorcitinib and INCA033989.

Bull case
  • Phase 1 monotherapy data showed a 33% objective response rate at the recommended 100 mg QD dose in heavily pretreated platinum-resistant ovarian cancer, with over 70% of patients experiencing tumor shrinkage, which compares favorably to the 10-15% typical response rate of chemotherapy in this setting (source: Targeted Oncology/ASCO 2025)
  • ESMO 2026 Phase 1 combination data with bevacizumab showed a 48% objective response rate (11 of 23 patients), including in patients who had already failed PARP inhibitors and prior bevacizumab (source: OncoDaily/ESMO 2026)
  • INCB123667 is the first CDK2-selective inhibitor to advance to Phase 3, giving Incyte a potential first-mover advantage in the CDK2 inhibitor class for cyclin E1-overexpressing ovarian cancer (source: PharmCube)
Bear case
  • Phase 3 data are years away (MAESTRA 2 estimated completion May 2029), with no near-term binary catalyst to drive share price, making this a low-impact story for the stock in the next 12 months (source: ClinicalTrials.gov NCT07214779)
  • Competition is intensifying: Pfizer's atirmociclib (CDK2-selective), Incyclix Bio's INX-315, Relay Therapeutics' RGT-419B (CDK2/4/6), and AstraZeneca's AZD8421 are all in clinical development, any of which could beat INCB123667 to market or show superior data (source: Eureka/CDK2 Competitive Landscape 2026)
  • Early Phase 1 data are based on small patient numbers (30 patients at the optimal dose), and response rates often drop in larger randomized Phase 3 trials
◆ mixed
Impact
PhasePhase 3
Time to marketIf Phase 3 DAWN-303 succeeds, earliest potential regulatory submission would be around 2029-2030, given topline data expected in 2028.

INCB161734 zecdarasib Updated Oct 29

What to watch

The ESMO 2026 Phase 1 data just landed (Oct 26) so this is the immediate catalyst cleared. The next major binary event is DAWN-303 Phase 3 topline data, expected no earlier than 2028 -- years out. In the nearer term, watch for Phase 3 adjuvant PDAC trial initiation (plans for 2027), the Genmab collaboration Phase 1/2 CRC study starting enrollment, and any competitive updates from Revolution Medicines' zoldonrasib program, which Incyte sees as its primary rival in the KRAS G12D space.

Bull case
  • Phase 1 data (ESMO 2026) showed a 89% confirmed objective response rate and 90% six-month landmark PFS when combined with mFOLFIRINOX in first-line metastatic PDAC, with a 100% disease control rate -- a standout result in a historically difficult-to-treat cancer (source: Investor press release Oct 26, 2026).
  • KRAS G12D is the most common KRAS mutation in pancreatic cancer (~40% of cases) and also prevalent in CRC (~15%), giving INCB161734 a large addressable patient population with significant unmet need (source: Annals of Oncology abstract).
  • Incyte is executing an aggressive clinical strategy with simultaneous Phase 3 (DAWN-303), planned adjuvant PDAC Phase 3, planned CRC Phase 3 (DAWN-302), and a Genmab collaboration for first-line CRC -- expanding the drug's potential across multiple indications (source: Incyte ESMO press release).
Bear case
  • Competition from Revolution Medicines' zoldonrasib (RMC-9805) is intense; zoldonrasib has already earned FDA Breakthrough Therapy designation for KRAS G12D NSCLC and is also being studied in pancreatic cancer -- Incyte sees itself as 'neck and neck' with RevMed in this space (source: FierceBiotech Oct 26, 2026).
  • The Phase 1 data, while impressive, comes from a small, single-arm cohort (n=27 for the mFOLFIRINOX cohort) and median PFS/mature overall survival data are not yet available; large randomized Phase 3 data are years away (2028), leaving significant clinical and regulatory risk (source: STAT News Oct 26, 2026).
  • Incyte's broader pipeline carries its own execution risk; the company reported Q3 2026 EPS of -$3.60, below estimates, highlighting near-term financial headwinds despite approved product revenue.

Other drugs in filings and trials

no drug report yet
  • Jakafi XR Last: Complete response letter · Jun 30, 2026
  • VGA039 Last: Breakthrough designation · Jun 8, 2026
  • povorcitinib Last: NDA filed · Mar 31, 2026 3 trials
  • NIKTIMVO Last: Approval · Aug 14, 2024
  • ZYNYZ Last: Approval · Mar 22, 2023
  • OPZELURA Last: Approval · Sep 21, 2021
  • PEMAZYRE Last: Approval · Apr 17, 2020
  • INCA034176 1 trial
  • INCB099280 2 trials
  • itacitinib 1 trial
  • Ruxolitinib 4 trials
  • Ruxolitinib 1.5% Cream 1 trial
  • Ruxolitinib Cream 1 trial
  • topical ruxolitinib 1.5% cream 1 trial

Past FDA events & how the stock moved

10 events
DateDrugEvent1 day5 days
Jun 30, 2026Jakafi XRComplete response letter−0.7%+2.3%
Jun 8, 2026VGA039Breakthrough designation+0.8%−0.4%
Jun 8, 2026VGA039Orphan drug designation+0.8%−0.4%
Jun 8, 2026VGA039Fast Track+0.8%−0.4%
Mar 31, 2026povorcitinibNDA filed+4.4%+6.2%
Dec 1, 2025INCA033989Breakthrough designation−2.9%−7.4%
Aug 14, 2024NIKTIMVOApproval−0.6%+3.4%
Mar 22, 2023ZYNYZApproval−1.7%−3.2%
Sep 21, 2021OPZELURAApproval−8.3%−9.5%
Apr 17, 2020PEMAZYREApproval+5.8%+8.2%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
INCA034176A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDPhase 2Active not recruiting32Jan 6, 2027
PovorcitinibA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaPhase 3Active not recruiting617Dec 26, 2026
topical ruxolitinib 1.5% creamStudy of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host DiseasePhase 2Completed · results24Oct 12, 2026
INCB099280A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaivePhase 2Terminated73Sep 30, 2026
INCB099280A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaPhase 2Terminated63Sep 28, 2026
TafasitamabTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsPhase 3Active not recruiting899Sep 1, 2026
INCB177054A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsPhase 2Terminated9Jul 29, 2026
retifanlimabSafety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.Phase 2Completed206May 29, 2026
itacitinibA Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibPhase 2Terminated18May 11, 2026
RuxolitinibA Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaPhase 2Completed171Mar 3, 2026
Ruxolitinib 10 MG Oral TabletRuxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated CorticosteroidsPhase 2Terminated10Feb 27, 2026
Ponatinib 15 MGStudy to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)Phase 2Completed34Dec 31, 2025
225Ac-SSO110 + SoCStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )Phase 2Terminated2Dec 31, 2025
ItacitinibAn Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerPhase 2Completed59Dec 24, 2025
RuxolitinibRuxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantPhase 2Terminated7Sep 17, 2025
INCAGN02385Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesPhase 2Completed · results61Aug 25, 2025
PemigatinibA Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaPhase 3Terminated · results167Jul 7, 2025
INCB099280A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsPhase 2Terminated · results5Jun 6, 2025
Ruxolitinib CreamA Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisPhase 3Completed · results241May 21, 2025
INCB000928INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersPhase 2Completed · results84Apr 1, 2025
RetifanlimabStudy of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckPhase 2Completed · results176Mar 14, 2025
Ruxolitinib CreamA Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoPhase 2Completed · results49Mar 6, 2025
PovorcitinibStudy Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaPhase 2Completed · results136Feb 28, 2025
Liposome-encapsulated Daunorubicin-CytarabineTesting the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsPhase 2Terminated · results12Feb 27, 2025
PovorcitinibA Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Phase 3Completed · results619Jan 7, 2025
Ruxolitinib CreamA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)Phase 3Completed · results190Dec 30, 2024
tafasitamabA Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)Phase 2Terminated · results54Oct 22, 2024
RuxolitinibPrevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT ModelPhase 2Completed40Oct 7, 2024
Ruxolitinib CreamA Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)Phase 3Completed · results204Oct 7, 2024
RuxolitinibRuxolitinib for Premalignant Breast DiseasePhase 2Completed · results84Aug 29, 2024
RuxolitinibRuxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.Phase 2Completed · results44May 1, 2024
carboplatinCarboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).Phase 3Completed · results308Apr 15, 2024
Ruxolitinib 1.5% CreamTopical Ruxolitinib 1.5% for Hidradenitis Suppurativa TreatmentPhase 2Terminated · results6Feb 23, 2024
RetifanlimabPlatinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerPhase 3Completed · results583Dec 15, 2023
RuxolitinibStudy Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerPhase 2Completed · results23Dec 31, 2022
BusulfanJAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisPhase 2Completed · results61Dec 28, 2022
PembrolizumabPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Phase 3Completed · results129Aug 22, 2018
PembrolizumabPembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Phase 3Completed · results89Jul 19, 2018
EpacadostatA Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaPhase 2Terminated50Dec 27, 2016
ItacitinibStudy of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerPhase 2Terminated9Feb 2016